1
|
Bérard M, Leducq S, Laribi K, Samaran R, Maillard H. Factors associated with efficacy of botulinum toxin A injections in primary axillary hyperhidrosis: a retrospective study of ninety patients. Dermatol Ther 2022; 35:e15620. [DOI: 10.1111/dth.15620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 05/12/2022] [Accepted: 06/02/2022] [Indexed: 11/29/2022]
Affiliation(s)
| | - Sophie Leducq
- Department of Dermatology and Reference Center for Rare Diseases and Vascular Malformations (MAGEC) CHRU Tours Tours France
| | - Kamel Laribi
- Department of Hematology Le Mans Hospital Le Mans France
| | - Romain Samaran
- Department of Dermatology Le Mans Hospital Le Mans France
| | - Hervé Maillard
- Department of Dermatology Le Mans Hospital Le Mans France
| |
Collapse
|
2
|
Asfour L, Moussa A, Littlewood Z, Sharif J, Newsham J, O'Donoghue N, Ogden S, McMullen E, Hunter H. Botulinum toxin A injections in the treatment of axillary hyperhidrosis: a prospective study reviewing quality of life and patient satisfaction in a UK tertiary dermatology centre. Clin Exp Dermatol 2022; 47:1358-1359. [PMID: 35262223 DOI: 10.1111/ced.15164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 02/26/2022] [Accepted: 02/27/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Leila Asfour
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK.,Sinclair Dermatology, Melbourne, Victoria, Australia
| | | | - Zoe Littlewood
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| | - Jennifer Sharif
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| | - John Newsham
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| | - Nuala O'Donoghue
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| | - Stephanie Ogden
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| | - Emma McMullen
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| | - Hamish Hunter
- Department of Dermatology, Salford Royal Foundation Trust, Manchester, UK
| |
Collapse
|
3
|
Reguero Del Cura L, Drake Monfort M, De Quintana Sancho A, González López MA. Perianal Hyperhidrosis Successfully Treated with Botulinum Toxin A. Skin Appendage Disord 2021; 7:404-407. [PMID: 34604333 DOI: 10.1159/000515492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Accepted: 02/25/2021] [Indexed: 11/19/2022] Open
Abstract
Perianal hyperhidrosis (HH) is a rare form of primary focal HH and may become a major problem for the patient with a significant psychosocial burden and negative impact on the quality of life. Botulinum toxin injections are widely used as a second-line treatment option for axillary, palmar, and plantar HH with a good safety profile. Herein, we pre-sent a case of primary perianal HH successfully treated with Botulinum toxin A at a dose higher than that previously reported in literature, with a longer response, a higher degree of satisfaction, and no adverse effects. Moreover, we review the main aspects of the perianal anatomy that are essential to carry out the technique correctly and make dermatologists achieve expertise with the procedure.
Collapse
Affiliation(s)
| | - Marta Drake Monfort
- Division of Dermatology, University Hospital Marqués de Valdecilla (U.H.M.V), Santander, Spain
| | | | | |
Collapse
|
4
|
Farrell J, Stewart T, Singh B, Singh G, Rosen R. Retrospective analysis of the efficacy and duration of botulinum toxin A injections in 30 patients with palmar hyperhidrosis. Intern Med J 2021; 51:1517-1521. [PMID: 34541778 DOI: 10.1111/imj.15489] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 03/10/2021] [Accepted: 03/28/2021] [Indexed: 11/29/2022]
Abstract
Palmar hyperhidrosis is a common disorder characterised by excessive sweating due to hyperfunction of the sweat glands. It can be classified as primary disease, or secondary to other causes. It has a high morbidity, and a range of treatment options. Botulinum toxin injections inhibit the release of acetylcholine from the presynaptic receptors. It is an effective treatment; however, it is infrequently selected as only axillary hyperhidrosis currently attracts a Medicare subsidy. We conducted a retrospective review of 30 patients at a Sydney dermatology clinic who received botulinum toxin injections for palmar hyperhidrosis within the past 5 years. This study has the largest patient cohort with this condition in Australia. There was evidence for a median reduction in the Hyperhidrosis Disease Severity Scale, a qualitative self-reported score, as well as an increasing duration of efficacy with repeated injections. There were minimal side-effects of weakness and numbness. There is also an association between treatment of palmar disease and improvement in plantar disease, which suggests that treatment of palmar hyperhidrosis should be considered earlier and more frequently.
Collapse
Affiliation(s)
- Joshua Farrell
- Department of Dermatology, Southern Suburbs, Sydney, New South Wales, Australia
| | - Thomas Stewart
- Department of Dermatology, Southern Suburbs, Sydney, New South Wales, Australia
| | - Bhavneet Singh
- Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Gurkirat Singh
- Department of Vascular Surgery, Nepean Hospital, Sydney, New South Wales, Australia
| | - Robert Rosen
- Department of Dermatology, Southern Suburbs, Sydney, New South Wales, Australia
| |
Collapse
|
5
|
Obed D, Salim M, Bingoel AS, Hofmann TR, Vogt PM, Krezdorn N. Botulinum Toxin Versus Placebo: A Meta-Analysis of Treatment and Quality-of-life Outcomes for Hyperhidrosis. Aesthetic Plast Surg 2021; 45:1783-1791. [PMID: 33619611 PMCID: PMC8316174 DOI: 10.1007/s00266-021-02140-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 01/10/2021] [Indexed: 11/24/2022]
Abstract
AIMS This study aims at assessing the treatment effect, disease severity and quality-of-life outcomes of botulinum toxin (BTX) injections for focal hyperhidrosis. METHODS We included randomized controlled trials of BTX injections compared with placebo for patients with primary or secondary focal hyperhidrosis. PubMed, Embase and the Cochrane Library were searched to August 2020. Gravimetric sweat rate reduction, disease severity measured by Hyperhidrosis Disease Severity Scale and quality-of-life assessment measured by Dermatology Life Quality Index were the outcomes of interest. Cochrane risk-of-bias tools were employed for quality assessment of given randomized controlled trials. RESULTS Eight studies met our inclusion criteria (n=937). Overall, risk bias was mixed and mostly moderate. BTX injections showed reduced risk in comparison with placebo for the gravimetric quantitative sweat reduction of > 50 % from baseline (risk difference: 0.63, 95% CI 0.51 to 0.74). Additionally, improvements were seen for disease severity and quality-of-life assessments evaluated by Hyperhidrosis Disease Severity Score reduction of ≥ 2 points (risk difference: 0.56, 95% CI 0.42 to 0.69) and mean change in Dermatology Life Quality Index (mean difference: - 5.55, 95% CI - 7.11 to - 3.98). The acquired data were insufficient to assess for long-term outcomes and limited to an eight-week follow-up period. CONCLUSIONS In focal axillary hyperhidrosis, BTX significantly reduces sweat production and yields superior outcomes in assessments of disease severity and quality-of-life. However, the quality-of-evidence is overall moderate and included studies account for short-term trial periods only. Further studies assessing BTX in comparison with first-line treatments for hyperhidrosis are warranted. LEVEL OF EVIDENCE III This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Collapse
Affiliation(s)
- Doha Obed
- Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
| | - Mustafa Salim
- Department of Hematology and Oncology, University Medical Center Goettingen, Goettingen, Germany
| | - Alperen S Bingoel
- Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
| | - Thurid R Hofmann
- Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
| | - Peter M Vogt
- Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
| | - Nicco Krezdorn
- Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
| |
Collapse
|
6
|
Lu Y, Zhao A, Meng X, Wang B, Song T, Xia Y. Hidden Blade Scalpel: A Useful Tool for the Treatment of Axillary Osmidrosis. Plast Surg (Oakv) 2020; 28:156-160. [PMID: 32879871 DOI: 10.1177/2292550320914080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background Axillary osmidrosis is a distressing problem that can particularly affect a patient's social life. In severe cases, patients may seek a surgical treatment to achieve a permanent effect. Many treatment techniques involving destruction or removal of the apocrine and eccrine glands have been developed. However, previous treatments have been hindered by surgical or aesthetic concerns. The purpose of this study was to evaluate the effect of the hidden blade scalpel procedure in treating axillary osmidrosis. Methods From December 2012 to December 2016, 372 patients with axillary osmidrosis underwent the hidden blade scalpel procedure. One 5-mm incision was made at approximately 1 cm beyond the axillary hairline. A hidden blade scalpel was then used to remove the subcutaneous tissue, including the plexus, apocrine and eccrine glands, and hair follicles, from the skin. The clinical efficacy was evaluated using a questionnaire. Results The hidden blade scalpel procedure resulted in a high percentage of patient satisfaction, a much shorter recovery time, and a low complication rate. Conclusion The hidden blade scalpel procedure is an effective method for the treatment of axillary osmidrosis.
Collapse
Affiliation(s)
- Ye Lu
- Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Aimin Zhao
- Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| | - Xiaohui Meng
- Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Binqing Wang
- Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Tao Song
- Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yang Xia
- Beijing Shijitan Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
7
|
Five-year follow-up of patients treated with intra-dermal botulinum toxin for axillary hyperhidrosis. Ir J Med Sci 2020; 189:1023-1026. [PMID: 31898163 DOI: 10.1007/s11845-019-02131-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Accepted: 10/26/2019] [Indexed: 10/25/2022]
Abstract
BACKGROUND Axillary hyperhidrosis is a common complaint affecting 5% of the general population. It can significantly impact quality of life (QOL) and may be extremely debilitating. Administration of intra-dermal botulinum toxin type-A (Botox) has been proven to be effective in managing axillary hyperhidrosis; however, to date, no long-term data has assessed its efficacy. AIM We aim to assess long-term (> 5 years) QOL outcomes in this patient cohort. METHODS In this single-centre series, all patients attending for axillary botox, with five or more years of follow-up, were prospectively included. QOL was assessed in all patients using the validated assessment tool, the modified Dermatology Life Quality Index (DLQI). Standard statistical methods were utilised with data reported as mean (± standard deviation). Subgroup analysis utilising previously published departmental data allowed for further assessment of change in QOL over time. RESULTS A total of 75 patients (83% female) met the inclusion criteria with 67% completing the DLQI assessment. Follow-up ranged from 5 to 10 years with a mean age of 37.6 years (± 8.82). The mean number of treatments over the study period was 12 (± 3.1). Mean overall post-treatment DLQI score was 1.6 (± 2.01). This represented a significant improvement in patient QOL (p = < 0.0001) associated with long-term botox application. This statistical significance was identified consistently across all components of the DLQI tool. CONCLUSION These data suggest that the established early QOL benefits associated with intra-dermal botox administration for AH are sustained in the long term. This benefit was seen across all subsets of the DLQI tool.
Collapse
|
8
|
Nawrocki S, Cha J. Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol 2019; 82:969-979. [PMID: 31811879 DOI: 10.1016/j.jaad.2019.11.042] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Revised: 11/15/2019] [Accepted: 11/22/2019] [Indexed: 01/17/2023]
Abstract
Hyperhidrosis is a dermatological condition defined by excessive sweating beyond thermoregulatory needs with significant effects on patients' quality of life. Hyperhidrosis is categorized as primary or secondary: primary hyperhidrosis is mostly focal and idiopathic, whereas secondary hyperhidrosis is commonly generalized and caused by an underlying medical condition or use of medications. Various surgical and nonsurgical therapies exist for primary hyperhidrosis. Although botulinum toxin is one of the deadliest toxins known, when used in small doses, it is one of the most effective therapies for primary hyperhidrosis. Botulinum toxin injections are widely used as a second-line primary hyperhidrosis treatment option once topical treatment strategies have failed. This article provides an overview of the commercially available botulinum toxin formulations and their applications in the treatment of primary hyperhidrosis.
Collapse
Affiliation(s)
- Shiri Nawrocki
- Rutgers-Robert Wood Johnson Medical School, Department of Dermatology, Piscataway, New Jersey.
| | - Jisun Cha
- Thomas Jefferson University, Department of Dermatology, Philadelphia, Pennsylvania
| |
Collapse
|
9
|
Hyperhidrose – Ätiopathogenese, Diagnostik, Klinik und Therapie. Hautarzt 2018; 69:857-869. [DOI: 10.1007/s00105-018-4265-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|